Extent and Rate of the drug absorbed the same
except if it 1. makes no medical difference 2. documented 3. not essential to effect
Back
Poison Prevention Packaging Act of 1970
Front
Requires use of child-resistant containers
Back
Potassium supplements
Front
NMT 50 meQ/dose
Back
Components of REMS
Front
1. Medication guides
2. Communication plans
3. Elements to assure safe use
Back
Right to Try
Front
1. Terminally ILL
2. Phase I trial
3. No FDA oversight
4.Manufacturer approval
Back
Betamethasone
Front
NMT 12.6 mg drug/pkg
Back
Investigation New Drug used when
Front
1. There is not comparable drug
2. There is no alternative drug
3. There is no controlled trials, or all trials completed
Back
Waxman-Hatch Act
Front
+Clinical studies are not needed for generics
Back
Can physicians make blanket prescriptions?
Front
No they can not
Back
Prednisone
Front
NMT 105 mg/pkg
Back
Prescription refills in PA
Front
1.Medication can not be substituted for another medication unless 1. Call pt and get approval 2. Call prescriber and get approval
Back
Drugs products that have a _____ therapeutic window will not be considered therapeutically equivalent
Front
narrow
Back
Nitroglycerin
Front
not required to be in CRC packaging
Back
Methylprednisone Tablets
Front
NMT 84 mg of drug/pkg
Back
Hospitals
Front
sometimes do not meet therapeutically equivalent products
Back
Aerosol prepaations intenteded for inhalation
Front
N/A
Back
REMS
Front
Risk Evaluation and Mitigation Strategy- the benefits of using it must outweigh risks
Back
B in the Orange book
Front
B means a documented or potential bioequivalence problem (does not mean it is worse than reference)
Back
STEPS
Front
Thialodmide
Back
What does a generic drug need to prove for generic equivalence?
Front
1. Bioequivalence
2. Bio availability
3. GMP
Back
Anhydrous chloestyramine
Front
N/A
Back
Mebendazole
Front
NMT 600 mg drug/pkg
Back
can you reuse child-resistant packaging?
Front
Only glass vials as long as new CRC cap is used
Back
Erythromycin granules
tablets
Front
NMT 8 gm of erythromycin
NMT 16 grams
Back
What if I can't reach the doctor but can reach the patient?
Front
Notify the doctor as soon as possible that you filled prescription from different manufacturer in emergency situation- legal
Back
Can manufacturers produce one package that is not child resistant?
Front
Yes, manufacturers can if they state on package is for households without young children or package not child resistant
Back
Oral contracpetives
Front
N/A
Back
A in the Orange book
Front
A means that a drug is therapeutically equivalent
Back
General rule: CRC
Front
all drugs must be in CRC
Back
Sodium Flouride
Front
NMT 110 mg of Sodium Flouridw per package ( 50 mg per package)- CRC
Back
Therepeutic equivalents have the same
Front
Active Ingredient
Strength
Dosage Form
Back
isosorbide dinitrate SL or chewable
Front
NMT 10 mg or less-CRC
Back
Orange book is not federal law
Front
drugs are substituted that sometimes that are not therapeutically equivalent; however, most states do this.
Back
Medroxyprogestrone
Front
N/A
Back
Patent term extensions
Front
2-5 years
New indication can be marketed for three years
no generic drug for five years
Back
Pharmaceutical equivalents that are bio equivalent
Front
assumed to be therapeutically equivalent
Back
Pancrealipase preparations
Front
N/A
Back
REMS safe use
Front
1. Special training or certification
2. Restricting distribution
3. Dispensing based on evidence safe conditions
4. Pt monitoring
One or more
Back
Waxman- Hatch Amendments
Front
how generic drugs get approved
Back
OTC
Front
Are mostly approved through monograph
Back
Colespitol
Front
up to 5 gm
Back
FTC comission monitors
Front
marketing of OTC drugs
Back
Therepeutic equivalents are Pharmceutical equivalents but with
Front
same ClinicaL EFFECT and efficacy
Back
Poison Prevention Packaging Act of 1970- enforced by
Front
Consumer Product Safety
Back
Unit dose- Under Poison Prevention Packaging Act
Front
can't open more than eight doses or toxic amount, whichever is less
Back
How to define a narrow therapeutic window drug?
Front
1. Less than a two fold difference between toxic dose and effective dose
2. Less than a two fold difference between lethal dose and effective dose
3. Carbamezepine, Phenyotin, warfarin, lithium, clonidine, levothyroxine
Back
FDA monitors
Front
marketing of prescription drugs
Back
Section 2
(50 cards)
Injunctive
Front
bring manufacturer to court
Back
In case of antibiotic drugs being provided for the manufacturer in granular form to be reconstituted by pharmacist, whose responsibility is it to provide child-resistant packaging?
Front
the pharmacist and manufacturer
Back
Whose responsibility maintains PPA?
Front
it is the dispensing pharmacist
Back
Good Manufacturing Practices
Front
Federal guidelines that must be followed by all entities that prepare and package medication or medical devices ( manufacturing, processing, packaging holding)
Back
If you think you have package site ,that is not susceptible to wear?
Front
Get information from manufacturer it is not susceptible to wear
Back
Sacrosidise in glycerol and water
Front
N/A
Back
Class I Recall
Front
Recall class where there is a reasonable possibility that the use/exposure to a violative product will cause serous adverse effects on health or death
Back
Dotterwich Case
Front
mislabeled information by accident
Back
Adulteration and Misbranding
Front
Most all violations of the FDCA are either ____ or ____, or both.
Back
Can I dispense easy open to nursing home?
Front
Yes, traditional nursing home where nurse can give med= institutions not needed.
Back
Adulteration
Front
making unpure poorer in quality
Back
Child resistant
Front
80 percent can't get acess to meds children less than 5
90 percent of adults can open it
Back
Who is ultimately responsible something complies with the PPPA of 1970?
Front
the pharmacist
Back
Class III recall definition
Front
Unlikely to cause adverse health consequences * typo)
Back
Poison Prevention Packaging Act of 1970- dosage form
Front
This is only for oral medications
Back
Park Case
Front
Acme put food in bad places and unsanitary places
Back
Can a physcian make a blanket waiver?
Front
No physician can not- only prescription can be filled this way
Back
drug recall: good faith defense?
Front
No, you did not check mail
Back
Seizure
Front
seize drugs off the shelf
Back
Items that don't need to be in tamper evidence packaging
Front
Dermatological
Dentrifice
Insulin
Lozenge
Back
Park Doctrine
Front
Park Case and Dottewich Case
Back
May the individual request that all of his/ her prescriptions be filled in conventional ( non-special packaging)?
Front
Yes; however one request is not a blanket waiver
Back
If a pt calls for information for poisoning?
Front
If you do not have emergency info needed, then call poison control center 1-800-222-1222
Back
F & D C 301 Prohibitions
Front
Adulteration and Misbranding
Back
Pudue Pharma
Front
downplayed oxycontin marketed as misbranding
Back
FDA: can it order removal of device off market
Front
YES it can
Back
FDA: can it order a drug off market
Front
No it can't
Back
Class II Recall
Front
The probability of serious harm is not likely and the effects may be temporary or reversable. This recall does not go to the customer level and is usually due to problems with consistency of potency ( remote probability of serious adverse effect)
Back
FDA can't directly order
Front
a drug to be removed from market
Back
Non-prescription packaging one size that does not comply
Front
is applicable
Back
Norethindrone
Front
50 mg of drug
Back
prescription vial failure
Front
if child gains acess to mes
Back
Where all the expemptions listed for the PPPA?
Front
PPPA regulations 16 CFR 1700 .14
Back
Unit dose packaging failure
Front
child gains access to those that have 8 or more pills or toxic dose
Back
PACKAGING PPPA VIOLATION
Front
CIVIL
CRIMINAL
ADMINISTRATIVE PENALTIES
Back
Mislabeling: good faith defense?
Front
Yes
Back
FDA enforcement act
Front
Injuctive relief ( seek court action)
Seizure ( libel action)- take drugs off shelf
Criminal proceedings- (fines and imprisonments)
Warning letter
Back
What is the responsbility of the pharmacist under PPPA?
Front
Poison Prevention packaging ACT- To dispense medication in poison control container unless patient, prescriber, or exceptions
Back
Must the customer make the choice for the conventional packaging in writing?
Front
No; however to protect yourself you might want to
Back
Did not catch recall?
Front
Civil liability
Back
Are IND susceptible to PPPAs standard?
Front
Yes
Back
FDA will inspect blank to determine_______ Adulteration
Front
1. The plant not every product
2. Health and safety better for community if FDA can monitor
Back
HRT that relies on progesterone and estrogen
Front
N/A
Back
What if you violate the PPPA?
Front
YOU CAN GO TO JAIL FOR A YEAR AND FINED UP TO 250,000
500,000 FINED ORGANIZATION
AND CIVILLY PROSECUTED IF HURT SOMEONE
Back
Prescription packaging one size that does not comply
Front
is not applicable
Back
Can a physician check a box to do this easy open waiver?
Front
Yes, prescribe can do this however not encouraged due to over non-child resistant caps
Back
Criminal proceedings
Front
against manufacturer
Back
Can I dispense easy open containers in hopsital?
Front
Yes, as long as patient is confined to hospital; however not in patient going out of hospital.
Back
Misbranding/ Adulteration- Ask youself?
Front
Strength, Quality, Purity
Back
warning letter
Front
to manufacturer
Back
Section 3
(23 cards)
Prescription Refill Authority
Front
1. Secretary- can authorize refill
2. Doctor can tell secretary to authorize refill ( Doctor must authorize- nurse or secretary can't)
3. Secretary- can relay info to Pharmacist
Back
IRB
Front
protects the health and welfare for pts.
Back
Tampered or not?
Front
1. Stopped by distinctive with design
2. Mess up logo could be tampered
Back
25 percent
Front
less than 2 years repack then need to take 25 percent of time
Back
Number ( for new drug)
Front
chemical type
Back
Misbranding
Front
the label is false or misleading
packaged or labeled in violation of PPPA
Pharmacist sells a drug without prescription or refills prescription without authorization
Back
Some prescriptions can be
Front
otc and rx
Back
if a drug gets a new indication
Front
by FDA approval NDA to get it approved for that use
Back
Supplemental NDA
Front
any minor changes in the Drug
Back
If something is not in tamper evident packaging that should be violation of
Front
adulteration, misbranding, or both
Back
Misbranding and Advertising
Front
Side effects, contraindications, and effectivenss
Back
Beyond use date for prescription vial
Front
1. Beyond use date not later than expiration
2. or one year from dispensing the medication
Whichever is sooner
Back
phase IV study
Front
continual evaluation of a drug after it has been released for marketing ( need to let FDA safety and efficacy)
Back
Beyond use date USP guidelines
Front
not adopted
Back
Drug facts panel
Front
- Active ingredients
- Purpose
-Use
- Warnings
- Directions
- Other info directed as monograph
-Inactive Ingredients
-Questions
Back
PA requirment beyond use date
Front
If less than a year, Do not use after ______ (date)
Back
S
Front
drug that is already equivalent
Back
P
Front
priority drug
- more effective
-more effective or safer
- greater convenience, less side effects, and improved tolerance or usefulness
Back
Beyond use date of 9/01/18 expiration needs to be
Front
09/01/20
Back
Items that do need to be in tamper evident package
Each state will have different prescriptive authority for different practiotioners
Back
Letter
Front
therapeutic potential
Back
Switch of Prescription Drugs to OTC
Front
A switch may occur in three ways:
1)The manufacturer may request the switch. Submit a supplemental application to its approved NDA
- marketing exclusivity
-from different manufacturer drug could be RX
2) Manufacturer can petition FDA
FDA- add a monograph or amend an existing monograph